Technical Analysis for AGTC - Applied Genetic Technologies Corporation

Grade Last Price % Change Price Change
grade C 4.28 0.71% 0.03
AGTC closed up 0.71 percent on Tuesday, March 19, 2019, on 66 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical AGTC trend table...

Date Alert Name Type % Chg
Mar 19 180 Bullish Setup Bullish Swing Setup 0.00%
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 18 200 DMA Resistance Bearish 0.71%
Mar 18 Bearish Engulfing Bearish 0.71%
Mar 18 Upper Bollinger Band Walk Strength 0.71%
Mar 18 Wide Bands Range Expansion 0.71%
Mar 18 Upper Bollinger Band Touch Strength 0.71%
Mar 15 200 DMA Resistance Bearish -2.73%
Mar 15 Shooting Star Candlestick Bearish -2.73%
Mar 15 Lizard Bearish Bearish Day Trade Setup -2.73%

Older signals for AGTC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. The company also completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, it has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Biotechnology Medical Specialties Diseases Alpha Gene Therapy Ophthalmology Age Related Macular Degeneration Retinitis Pigmentosa Vision Antitrypsin Deficiency Eye Diseases Gene Therapy Products X Linked Retinitis Pigmentosa Retinoschisis
Is AGTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.5
52 Week Low 2.26
Average Volume 105,794
200-Day Moving Average 4.5802
50-Day Moving Average 3.4243
20-Day Moving Average 3.9015
10-Day Moving Average 4.102
Average True Range 0.2797
ADX 34.51
+DI 28.2213
-DI 15.7752
Chandelier Exit (Long, 3 ATRs ) 3.9009
Chandelier Exit (Short, 3 ATRs ) 3.8991
Upper Bollinger Band 4.4843
Lower Bollinger Band 3.3187
Percent B (%b) 0.82
BandWidth 29.875689
MACD Line 0.2353
MACD Signal Line 0.2036
MACD Histogram 0.0317
Fundamentals Value
Market Cap 77.41 Million
Num Shares 18.1 Million
EPS 0.63
Price-to-Earnings (P/E) Ratio 6.79
Price-to-Sales 1.74
Price-to-Book 0.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.64
Resistance 3 (R3) 4.61 4.45 4.58
Resistance 2 (R2) 4.45 4.36 4.47 4.56
Resistance 1 (R1) 4.36 4.30 4.41 4.40 4.54
Pivot Point 4.21 4.21 4.23 4.22 4.21
Support 1 (S1) 4.12 4.11 4.16 4.16 4.02
Support 2 (S2) 3.96 4.06 3.98 4.00
Support 3 (S3) 3.88 3.96 3.98
Support 4 (S4) 3.92